Factors influencing the outcome of vedolizumab treatment: Real-life data with objective outcome measurements.

In a real-life national cohort setting, VDZ induced remission in more than half of IBD patients. Previous treatment with anti-TNF agents was associated with a significant lower efficacy of VDZ in UC but not in CD patients.